Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,637 shares of the biopharmaceutical company’s stock after purchasing an additional 2,218 shares during the period. Clear Harbor Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,981,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox raised its stake in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the second quarter worth about $628,151,000. Acadian Asset Management LLC lifted its holdings in Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after acquiring an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 26.5% in the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after purchasing an additional 225,078 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and lifted its price target to $860, citing improving fundamentals and 2026 catalysts, a clear bullish catalyst for the stock. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Truist raised its price target to $820 and reiterated a Buy, adding incremental upside and supporting analyst-driven demand. Truist raises price target
• Positive Sentiment: Aggregated analyst coverage is shifting more positive (multiple upgrade pieces and a roundup of 21 analyst views), which can drive buy-side interest and shorten-term momentum. 21 analysts assess Regeneron
• Neutral Sentiment: Unusual options activity has been reported, indicating increased speculative positioning and hedging that can amplify intraday moves but is ambiguous for longer-term direction. Unusual options activity
• Neutral Sentiment: Coverage pieces note falling short interest and renewed bullish cases; lower short interest reduces short-squeeze potential but supports steadier upside if fundamentals hold. Analyst upgrades and short-interest drop
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 on Jan. 7, which can be viewed by some investors as a signal to take profits. Director share sale disclosed

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $801.01 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $816.99. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $84.19 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.42 and a beta of 0.39. The business has a fifty day simple moving average of $735.23 and a 200-day simple moving average of $626.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the business earned $12.46 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. UBS Group upped their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. HSBC initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Finally, Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the company from $627.00 to $860.00 in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $791.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.